Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neoplasm with neuroendocrine differentiation that arises from the small or large intestine. It includes well differentiated neuroendocrine tumors (low and intermediate grade) and poorly differentiated neuroendocrine carcinomas (high grade).
Biomarker and diagnostic research for intestinal neuroendocrine neoplasm has been reported in the published literature.
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
108 publications have been identified in PubMed for intestinal neuroendocrine neoplasm. Kisho has analyzed 29 by research type. Research spans Review / Meta-Analysis (48%), Basic Science / Preclinical (17%), and Clinical Trial Publication (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 14 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:57 PM UTC
Laboratory research | 5 | 17% |
Clinical study results | 4 | 14% |
Testing and diagnosis research | 3 | 10% |
Disease patterns and progression | 2 | 7% |
Patient case studies | 1 | 3% |
Vijayvergia N (2026). [PMID: 41236448](https://pubmed.ncbi.nlm.nih.gov/41236448/). *Gastroenterology*. [Review / Meta-Analysis]
Slott C (2026). [PMID: 41709663](https://pubmed.ncbi.nlm.nih.gov/41709663/). *J Neuroendocrinol*. [Clinical Trial Publication]
Thummalapalli R (2025). [PMID: 41264896](https://pubmed.ncbi.nlm.nih.gov/41264896/). *JCO Precis Oncol*. [Diagnostic / Biomarker]
Moorman A (2025). [PMID: 39478232](https://pubmed.ncbi.nlm.nih.gov/39478232/). *Nature*. [Basic Science / Preclinical]
Somech E (2025). [PMID: 40699214](https://pubmed.ncbi.nlm.nih.gov/40699214/). *Elife*. [Basic Science / Preclinical]
Szóstak N (2025). [PMID: 39998665](https://pubmed.ncbi.nlm.nih.gov/39998665/). *Cancer Immunol Immunother*. [Epidemiology / Natural History]
Kolodziej M (2025). [PMID: 41404513](https://pubmed.ncbi.nlm.nih.gov/41404513/). *Front Endocrinol (Lausanne)*. [Clinical Trial Publication]
Liu S (2025). [PMID: 40214675](https://pubmed.ncbi.nlm.nih.gov/40214675/). *Cancer Immunol Immunother*. [Review / Meta-Analysis]
Aktypis C (2025). [PMID: 39738890](https://pubmed.ncbi.nlm.nih.gov/39738890/). *Endocrine*. [Epidemiology / Natural History]
Wang W (2025). [PMID: 40482913](https://pubmed.ncbi.nlm.nih.gov/40482913/). *Cancer Lett*. [Basic Science / Preclinical]